Medicinova Inc (MNOV)

$1.30 -0.04 (-2.93%)
Market Cap 66.22M
Revenue (ttm) 0.00
Net Income (ttm) -11.04M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 47,400
Avg Vol 29,940
Day's Range N/A - N/A
Shares Out 49.05M
Stochastic %K 5%
Beta 0.35
Analysts Strong Sell
Price Target $8.00

Company Profile

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2b/3 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical my...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 373 1500
Fax: 858 404 0048
Address:
4275 Executive Square, Suite 300, La Jolla, United States
All_Nothing
All_Nothing Aug. 1 at 2:59 PM
$MNOV MediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 Million. 3% purchase discount for the next 3 years. https://investors.medicinova.com/node/13216/html
2 · Reply
All_Nothing
All_Nothing Jul. 25 at 6:25 PM
$MNOV finally some good news. Now how about some information on the monetary damages!?
0 · Reply
Corpius
Corpius Jul. 25 at 4:20 PM
$MNOV interesting buys and volume. no news. insider buys before big PR?
0 · Reply
hitmongreen
hitmongreen Jul. 24 at 5:10 PM
$MNOV 🤔
0 · Reply
Lionish
Lionish Jul. 24 at 2:33 PM
$MNOV Make sure you are invested and be patient…
1 · Reply
JarvisFlow
JarvisFlow Jul. 24 at 1:00 PM
D. Boral Capital has updated their rating for MediciNova ( $MNOV ) to Buy with a price target of 9.
0 · Reply
BigSqueezeComing
BigSqueezeComing Jul. 24 at 10:25 AM
$MNOV pt 1.5
0 · Reply
BigSqueezeComing
BigSqueezeComing Jul. 24 at 10:24 AM
$MNOV MediciNova is nearing full enrollment in both the ALS and metabolic/lipid trials, marking important milestones toward readouts—potentially late 2026 for ALS and mid‑term outcomes for the MN‑001 metabolic study.
0 · Reply
BigSqueezeComing
BigSqueezeComing Jul. 24 at 10:14 AM
$MNOV MediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical Trials By MediciNova, Inc. | July 24, 2025, 6:00 AM
0 · Reply
blz90
blz90 Jul. 23 at 7:42 AM
$MNOV This is dead.
0 · Reply
Latest News on MNOV
MediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 Million

Jul 31, 2025, 7:30 PM EDT - 12 days ago

MediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 Million

MediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical Trials

Jul 24, 2025, 6:00 AM EDT - 19 days ago

MediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical Trials

MediciNova To Participate in D. Boral's Capital Global Conference on May 14, 2025

Apr 14, 2025, 7:00 PM EDT - 4 months ago

MediciNova To Participate in D. Boral's Capital Global Conference on May 14, 2025

First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients

Apr 8, 2025, 7:00 PM EDT - 4 months ago

First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients

MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND

Dec 5, 2024, 6:00 PM EST - 8 months ago

MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND

MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver

Nov 14, 2024, 6:00 PM EST - 9 months ago

MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver

MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis

Nov 11, 2024, 6:00 PM EST - 9 months ago

MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis

MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium)

Oct 23, 2024, 7:00 PM EDT - 10 months ago

MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium)

MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)

Sep 30, 2024, 9:00 AM EDT - 11 months ago

MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND

Sep 9, 2024, 7:00 PM EDT - 1 year ago

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND

MediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) Meeting

Sep 3, 2024, 7:00 PM EDT - 1 year ago

MediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) Meeting

MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition

Aug 29, 2024, 7:00 PM EDT - 1 year ago

MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition

MediciNova Chief Business Officer David H. Crean, Ph.D.

Jun 20, 2024, 6:00 AM EDT - 1 year ago

MediciNova Chief Business Officer David H. Crean, Ph.D.

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer

Jun 5, 2024, 6:00 AM EDT - 1 year ago

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer

MediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024

Jun 3, 2024, 6:00 AM EDT - 1 year ago

MediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024

MediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 (Tipelukast) for Cardiometabolic Conditions

May 28, 2024, 6:00 AM EDT - 1 year ago

MediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 (Tipelukast) for Cardiometabolic Conditions

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Eye Cancer

May 20, 2024, 6:00 AM EDT - 1 year ago

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Eye Cancer

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome

May 14, 2024, 6:00 AM EDT - 1 year ago

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome

MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast)

May 7, 2024, 6:00 AM EDT - 1 year ago

MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast)

MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)

Apr 2, 2024, 7:00 PM EDT - 1 year ago

MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan

Mar 26, 2024, 7:00 PM EDT - 1 year ago

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan

MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis Society

Mar 20, 2024, 7:00 PM EDT - 1 year ago

MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis Society

MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology

Mar 12, 2024, 6:30 AM EDT - 1 year ago

MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology

MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China

Jan 17, 2024, 6:00 AM EST - 1 year ago

MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology

Dec 21, 2023, 6:00 PM EST - 1 year ago

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology

MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe

Dec 6, 2023, 6:00 PM EST - 1 year ago

MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe

MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology

Nov 19, 2023, 6:00 PM EST - 1 year ago

MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology

MediciNova's Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of Phenylketonuria

Oct 27, 2023, 1:00 AM EDT - 1 year ago

MediciNova's Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of Phenylketonuria

MediciNova Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada

Oct 10, 2023, 7:00 PM EDT - 2 years ago

MediciNova Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada

MediciNova Receives Gene Therapy Milestone Payment

Oct 4, 2023, 7:00 PM EDT - 2 years ago

MediciNova Receives Gene Therapy Milestone Payment

MediciNova Announces Results of Studies under BARDA Contract to Develop MN 166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury

Sep 27, 2023, 7:00 PM EDT - 2 years ago

MediciNova Announces Results of Studies under BARDA Contract to Develop MN 166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-Oncology

Aug 17, 2023, 7:00 PM EDT - 2 years ago

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-Oncology

MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Europe

Aug 16, 2023, 7:00 PM EDT - 2 years ago

MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Europe

MediciNova Receives a New Patent Covering MN-001 for the Treatment of Scleroderma and Systemic Sclerosis in Europe

Aug 15, 2023, 7:00 PM EDT - 2 years ago

MediciNova Receives a New Patent Covering MN-001 for the Treatment of Scleroderma and Systemic Sclerosis in Europe

MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Europe

Aug 14, 2023, 7:00 PM EDT - 2 years ago

MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Europe

MediciNova Announces Presentation of Results from the Phase 2b Trial of MN-166 (ibudilast) in Alcohol Use Disorder at the 46th Annual Research Society on Alcohol (RSA) Scientific Meeting

Jun 29, 2023, 6:00 AM EDT - 2 years ago

MediciNova Announces Presentation of Results from the Phase 2b Trial of MN-166 (ibudilast) in Alcohol Use Disorder at the 46th Annual Research Society on Alcohol (RSA) Scientific Meeting

MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for Patients with Microorganism Infection in Europe

May 14, 2023, 7:00 PM EDT - 2 years ago

MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for Patients with Microorganism Infection in Europe

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 for the Treatment of Advanced NASH in Canada

Apr 30, 2023, 7:00 PM EDT - 2 years ago

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 for the Treatment of Advanced NASH in Canada

MediciNova Announces Additional Extension of BARDA Contract to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury

Mar 9, 2023, 6:00 PM EST - 2 years ago

MediciNova Announces Additional Extension of BARDA Contract to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury

MediciNova Announces New Data Regarding MN-166 (ibudilast) in Glioblastoma Tumor Tissue Analysis Presented at the 20th Annual World Congress of Society for Brain Mapping and Therapeutics

Feb 20, 2023, 6:00 PM EST - 2 years ago

MediciNova Announces New Data Regarding MN-166 (ibudilast) in Glioblastoma Tumor Tissue Analysis Presented at the 20th Annual World Congress of Society for Brain Mapping and Therapeutics

MediciNova Announces Health Canada Grants Authorization to Commence Multi-arm Phase 2/3 Clinical Trial to Evaluate MN-166 (ibudilast) in Long COVID

Feb 8, 2023, 6:00 PM EST - 2 years ago

MediciNova Announces Health Canada Grants Authorization to Commence Multi-arm Phase 2/3 Clinical Trial to Evaluate MN-166 (ibudilast) in Long COVID

MediciNova Announces Completion of Enrollment in the Phase 2b Clinical Trial of MN 166 (ibudilast) in Alcohol Use Disorder

Jan 30, 2023, 6:00 PM EST - 2 years ago

MediciNova Announces Completion of Enrollment in the Phase 2b Clinical Trial of MN 166 (ibudilast) in Alcohol Use Disorder

MediciNova Announces Completion of Enrollment in the Phase 2 Clinical Trial Evaluating MN-166 (ibudilast) for Treatment of Recurrent and Newly Diagnosed Glioblastoma

Jan 12, 2023, 6:00 PM EST - 2 years ago

MediciNova Announces Completion of Enrollment in the Phase 2 Clinical Trial Evaluating MN-166 (ibudilast) for Treatment of Recurrent and Newly Diagnosed Glioblastoma

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Scleroderma and Systemic Sclerosis in Canada

Jan 10, 2023, 10:00 PM EST - 2 years ago

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Scleroderma and Systemic Sclerosis in Canada

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Brazil

Jan 9, 2023, 10:00 PM EST - 2 years ago

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Brazil

MediciNova to Meet with U.S. FDA to Discuss Clinical Development of a Parenteral Formulation of MN-166 (ibudilast)

Jan 5, 2023, 6:00 PM EST - 2 years ago

MediciNova to Meet with U.S. FDA to Discuss Clinical Development of a Parenteral Formulation of MN-166 (ibudilast)

MediciNova Announces Additional Positive Results Regarding the Effects of MN-001 (tipelukast) on Serum Lipid Panel in Type 2 Diabetes and NAFLD Patients Presented at IDF 2022 Congress, the Annual Meeting of the International Diabetes Federation

Dec 6, 2022, 6:00 PM EST - 2 years ago

MediciNova Announces Additional Positive Results Regarding the Effects of MN-001 (tipelukast) on Serum Lipid Panel in Type 2 Diabetes and NAFLD Patients Presented at IDF 2022 Congress, the Annual Meeting of the International Diabetes Federation

MediciNova Announces Positive Results from Secondary Analysis of Phase 2 Trial of MN-166 (ibudilast) Published in The American Journal of Drug and Alcohol Abuse

Dec 5, 2022, 6:00 PM EST - 2 years ago

MediciNova Announces Positive Results from Secondary Analysis of Phase 2 Trial of MN-166 (ibudilast) Published in The American Journal of Drug and Alcohol Abuse

MediciNova to Participate in the Lytham Partners Fall 2022 Investor Conference

Sep 15, 2022, 7:00 PM EDT - 3 years ago

MediciNova to Participate in the Lytham Partners Fall 2022 Investor Conference

MediciNova Receives Issue Notification for a New Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma

Sep 14, 2022, 7:00 PM EDT - 3 years ago

MediciNova Receives Issue Notification for a New Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma

All_Nothing
All_Nothing Aug. 1 at 2:59 PM
$MNOV MediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 Million. 3% purchase discount for the next 3 years. https://investors.medicinova.com/node/13216/html
2 · Reply
All_Nothing
All_Nothing Jul. 25 at 6:25 PM
$MNOV finally some good news. Now how about some information on the monetary damages!?
0 · Reply
Corpius
Corpius Jul. 25 at 4:20 PM
$MNOV interesting buys and volume. no news. insider buys before big PR?
0 · Reply
hitmongreen
hitmongreen Jul. 24 at 5:10 PM
$MNOV 🤔
0 · Reply
Lionish
Lionish Jul. 24 at 2:33 PM
$MNOV Make sure you are invested and be patient…
1 · Reply
JarvisFlow
JarvisFlow Jul. 24 at 1:00 PM
D. Boral Capital has updated their rating for MediciNova ( $MNOV ) to Buy with a price target of 9.
0 · Reply
BigSqueezeComing
BigSqueezeComing Jul. 24 at 10:25 AM
$MNOV pt 1.5
0 · Reply
BigSqueezeComing
BigSqueezeComing Jul. 24 at 10:24 AM
$MNOV MediciNova is nearing full enrollment in both the ALS and metabolic/lipid trials, marking important milestones toward readouts—potentially late 2026 for ALS and mid‑term outcomes for the MN‑001 metabolic study.
0 · Reply
BigSqueezeComing
BigSqueezeComing Jul. 24 at 10:14 AM
$MNOV MediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical Trials By MediciNova, Inc. | July 24, 2025, 6:00 AM
0 · Reply
blz90
blz90 Jul. 23 at 7:42 AM
$MNOV This is dead.
0 · Reply
JarvisFlow
JarvisFlow Jun. 16 at 5:35 PM
B. Riley Securities has updated their rating for MediciNova ( $MNOV ) to Buy with a price target of 5.
0 · Reply
Jac1962
Jac1962 Jun. 12 at 4:52 PM
$MNOV Shareholder's Getting Stepped All over..
1 · Reply
Jac1962
Jac1962 Jun. 10 at 10:41 PM
$MNOV Whats Up Medic Nova Why Are You Sleeping......Give Us Some Positive News......You Say You Are A Biotech Well Act Like one.
0 · Reply
micros24
micros24 Jun. 10 at 9:30 PM
$MNOV
1 · Reply
All_Nothing
All_Nothing Jun. 9 at 1:22 PM
$MNOV 7 months after the notice to receive monetary damages and still no details.
2 · Reply
thepalace2007
thepalace2007 May. 20 at 2:41 PM
$MNOV super
1 · Reply
Amoore0107
Amoore0107 May. 20 at 1:16 PM
$MNOV very very soon!!
2 · Reply
All_Nothing
All_Nothing May. 14 at 6:27 PM
$MNOV
1 · Reply
Jac1962
Jac1962 May. 12 at 12:10 PM
$MNOV Something Not Right Here.....
1 · Reply
Jac1962
Jac1962 Apr. 30 at 11:27 AM
$MNOV Where's The Settlement.....
1 · Reply
blz90
blz90 Apr. 29 at 4:39 PM
$MNOV why this is so dead.
0 · Reply
JarvisFlow
JarvisFlow Apr. 9 at 11:30 AM
D. Boral Capital has updated their rating for MediciNova ( $MNOV ) to Buy with a price target of 9.
0 · Reply